BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27833094)

  • 1. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
    Malani D; Murumägi A; Yadav B; Kontro M; Eldfors S; Kumar A; Karjalainen R; Majumder MM; Ojamies P; Pemovska T; Wennerberg K; Heckman C; Porkka K; Wolf M; Aittokallio T; Kallioniemi O
    Leukemia; 2017 May; 31(5):1187-1195. PubMed ID: 27833094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.
    Wu B; Mao ZJ; Wang Z; Wu P; Huang H; Zhao W; Zhang L; Zhang Z; Yin H; Gale RP; Yin B
    Acta Haematol; 2021; 144(5):534-541. PubMed ID: 33626530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
    Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
    Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
    Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
    Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.
    Kurata M; Rathe SK; Bailey NJ; Aumann NK; Jones JM; Veldhuijzen GW; Moriarity BS; Largaespada DA
    Sci Rep; 2016 Nov; 6():36199. PubMed ID: 27808171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
    Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
    Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
    Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
    Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.
    Levin M; Stark M; Berman B; Assaraf YG
    Cell Death Dis; 2019 May; 10(6):390. PubMed ID: 31101804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine.
    Visser N; Lourens HJ; Huls G; Bremer E; Wiersma VR
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33652766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
    Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
    Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
    Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
    Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
    BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ULK2 Is a Key Pro-Autophagy Protein That Contributes to the High Chemoresistance and Disease Relapse in FLT3-Mutated Acute Myeloid Leukemia.
    Lai J; Yang C; Shang C; Chen W; Chu MP; Brandwein J; Lai R; Wang P
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [FLT3 inhibitors for acute myeloid leukemia].
    Kiyoi H
    Nihon Rinsho; 2014 Jun; 72(6):1035-41. PubMed ID: 25016800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.
    Yan H; Wen L; Tan D; Xie P; Pang FM; Zhou HH; Zhang W; Liu ZQ; Tang J; Li X; Chen XP
    Oncotarget; 2017 Jan; 8(1):1529-1540. PubMed ID: 27903973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.